Dr. Sven Rihm

Counsel

慕尼黑 + 49.89.20.60.42.200

联系：

Share

Dr. Sven Rihm is a German and European patent lawyer who has been advising clients for almost 25 years on all aspects of intellectual property law. In addition to decades of experience in obtaining and securing intellectual property rights, he has extensive practical experience in opposition, appeal, and nullity proceedings before the German and European Patent Offices, the Federal Patent Court, and the Unified Patent Court. Sven also advises on matters relating to supplementary protection certificates (SPCs) and prepares freedom-to-operate and due diligence analyses, as well as patent validity opinions.

His academic background enables him to advise clients on all technical aspects in the fields of organic, inorganic, and technical chemistry, as well as on technologies in the fields of life sciences, biotechnology, and pharmaceuticals.

Prior to joining Jones Day, Sven practiced at one of Germany's largest law firms and at a small German IP boutique.

Sven is a member of the German Patent Lawyer's Association (PAK), the Institute of Professional Representatives before the European Patent Office (epi), the International Federation of Industrial Property Attorneys (FICPI), and the Association of Intellectual Property Experts (VPP).

经验

  • LyondellBasell acquires APKJones Day advised LyondellBasell in the acquisition of APK AG in Merseburg, Germany.
  • Vibrantz moves to invalidate sinter paste patent before Unified Patent Court in MunichJones Day represents Vibrantz GmbH, a manufacturer of specialty chemicals and materials, in patent invalidation counterclaim proceedings before the Unified Patent Court, Munich local division, in a dispute over certain precious metal sinter pastes for chip bonding.
  • Vibrantz defends patent dispute before Unified Patent Court in MunichJones Day represents Vibrantz GmbH, a manufacturer of specialty chemicals and materials, in patent litigation before the Unified Patent Court, Munich local division, in a dispute over certain precious metal sinter pastes for chip bonding.
  • Idenix enforces patent against Gilead in Germany over sofosbuvirJones Day represented Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in patent litigation against Gilead in Landgericht Düsseldorf in Germany over sofosbuvir, the active ingredient in Sovaldi® and Harvoni®, Gilead's blockbuster drugs for treating Hepatitis C.
  • Idenix defends nucleoside analogue patent in EPO opposition against five opponentsJones Day represented Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in opposition proceedings before the EPO related to Idenix patent covering nucleoside analogs and prodrugs.
  • Milliken & Company acquires Zebra-chemJones Day advised Milliken & Company in its acquisition of Zebra-chem GmbH, a global chemicals company known for its peroxide and blowing agent masterbatches.
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • Global manufacturer of specialty adhesives enforces hotmelt adhesive patent against major German competitorJones Day represents a manufacturer of specialty adhesives in patent litigation against a major German competitor before the courts in Düsseldorf and the German Federal Patent Court.
    •

    October 2022 Alert

    The Days are Numbered for the EPO's 10-Day Rule

    April 2020 Alert

    COVID-19 Accelerates Digital Transformation at the European Patent Office

    March 2017 Commentary

    Antidote to Toxic Divisionals—European Patent Office Rules on Partial Priorities

    June 2015 Alert

    The EPO's Undisclosed Disclaimers Trap—A Possible Way Out

    发送前请注意

    *Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice